Zirabev is Pfizer’s biosimilar of Genentech’s Avastin, which is used to treat cancers including metastatic colorectal cancer, lung cancer, cervical cancer and renal cell carcinoma. Zirabev is 23 percent cheaper than Avastin.
Ruxience is Pfizer’s biosimilar of Roche’s Rituxan, used to treat non-Hodgkin’s lymphoma and some types of leukemia. It is 24 percent cheaper than Rituxan.
Trazimara is Pfizer’s biosimilar of Roche’s Herceptin, used to treat certain types of breast cancer. It is 22 percent cheaper than Herceptin.
Zirabev came to the U.S. market Dec. 31, Ruxience came to market Jan. 23, and Trazimera will come out Feb. 15.
Read the full news release here.
More articles on pharmacy:
BCBS, Civica Rx create subsidiary to cut generic drug costs
PhRMA spent a record $29M on lobbying in 2019
Former Insys CEO gets 30 months in prison
